

## **Md Yuzaiful Md Yusof**



**Country:** United Kingdom

**Contact e-mail:** y.yusof@leeds.ac.uk

**Year of birth:** 1983

### **Mains diplomas:**

PhD: Final Year Trainee – Expected to complete by May 2019

Medical Degree: MBChB (University of Manchester, 2008)

Other: MRCP (UK), PG Diploma in Health Research (University of Leeds)

### **Current position and hospital/university:**

December 2014 – Present: NIHR Doctoral Research Fellow at Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, UK

August 2012 – Present: Specialist Registrar (ST5) in Rheumatology at Leeds Teaching Hospitals NHS Trust, UK

### **Position within EULAR/international experience:**

2015 – Present: Appointed as a Reviewer for Annals of the Rheumatic Diseases journal following completion of EMEUNET Peer Review Mentoring Programme

### **Role as EMEUNET working group member:**

June 2017 – Present: Elected as EULAR/EMEUNET Working Group member on the Newsletter sub-group

### **Areas of Research/Interest:**

Systemic Lupus Erythematosus (SLE), B-cell Therapies, ANCA-associated Vasculitis, Infection, Biomarkers and Personalised Medicine

## **Selected Publications:**

1. **Md Yusof MY**, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. *Ann Rheum Dis*. 2017 Jul 6. pii: annrheumdis-2017-211191. doi: 10.1136/annrheumdis-2017-211191. [Epub ahead of print]
2. **Md Yusof MY**, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, Dass S and Emery P. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre. *Rheumatology (Oxford)*. 2017 Apr 24. doi: 10.1093/rheumatology/kex072. [Epub ahead of print]
3. Bissell LA, **Md Yusof MY**, Buch MH. Primary myocardial disease in scleroderma – a comprehensive review of the literature to inform the UKSSSG (UK Systemic Sclerosis Study Group) cardiac working group. *Rheumatology (Oxford)*. 2017 Jun 1;56(6):882-895. doi: 10.1093/rheumatology/kew364.
4. Zayat AS, **Md Yusof MY**, Wakefield RJ, Conaghan PG, Vital EM and Emery P. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. *Rheumatology (Oxford)*. 2016 Mar;55(3):485-94.
5. **Md Yusof MY**, Vital EM and Buch MH. B cell therapies, approved and emerging: a review of infectious risk and prevention during use. *Current Rheumatology Rep*. 2015 Oct;17(10):539.
6. **Md Yusof MY**, Vital EM, Das S, Dass, Arumugakani G, Savic S, Rawstron AC, Emery P. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions. *Ann Rheum Dis*. 2015 Sep;74(9):1734-8.
7. Vital EM, Wittmann M, Edward S, **Md Yusof MY**, MacIver H, Pease CT, Goodfield M, Emery P. Brief Report: Responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. *Arthritis Rheumatol*. 2015 Jun;67(6):1586-91.
8. **Md Yusof MY**, Vital EM and Emery P. Biologics in systemic lupus erythematosus: current options and future perspectives. *Br J Hosp Med (Lond)*. 2014 Aug;75(8):440-7
9. **Md Yusof MY**, Vital EM and Emery P. Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. *Arthritis Care Res (Hoboken)*. 2014 Oct;66(10):1591-3.
10. **Md Yusof MY**, Vital EM and Emery P. B-cell-targeted therapies in systemic lupus erythematosus (SLE) and ANCA-associated vasculitis: Current progress. *Expert Rev Clin Immunol*. 2013 Aug; 9(8):761-72.

## **Date of last CV updated:**

20 July 2017